Project Grant R21CA293759
Award Date
5/15/25
Completion Date
4/30/27
Dollars Obligated
$442K
Federal Agency
National Cancer Institute
Federal Grant Program
93.393
Assistance Type
Project Grant
Place of Performance
Massachusetts, USA
Similar Awards
This $2,136,715 federal Project Grant award from the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research program (CFDA 93.393) is funding a 4-year research project focused on "Harnessing DNA Methylation in Peripheral Blood for Improved Colorectal Cancer Prevention." The primary awardee is the President and Fellows of Harvard College, specifically the Harvard T.H. Chan School of Public Health. Key sub-awards were provided to the Dana-Farber Cancer Institute,...
This federal Project Grant award from the National Cancer Institute (NCI), under the Cancer Cause and Prevention Research program (CFDA 93.393), is supporting research at the Van Andel Research Institute (VAI) in Grand Rapids, Michigan to investigate the mechanisms of DNA methylation signaling and dysregulation in colon cancer. The $632,319 award, with a period of performance from July 2, 2024 to June 30, 2029, aims to characterize the ubiquitin signaling network regulating the activity of the...
The National Cancer Institute (NCI) awarded a $662,918 Project Grant (CFDA 93.394 - Cancer Detection and Diagnosis Research) to Duke University to plan and pilot test a weight management intervention for African American breast cancer survivors. The project aims to adapt evidence-based weight loss materials from prior studies and integrate them with the nationwide Take Off Pounds Sensibly (TOPS) community-based program. The planned intervention will transition participants from a dietitian-led...
The National Cancer Institute (NCI) awarded a $187,000 Project Grant under the Cancer Cause and Prevention Research (CFDA 93.393) program to Northwestern University for the project "Lipid-Initiated Epigenetic Reprogramming of the Breast to a Neural Phenotype." This innovative research aims to explore how changes in lipid metabolism pathways and associated epigenetic modifications may contribute to the development of estrogen receptor-negative breast cancer. The study utilizes an in...
The National Cancer Institute (NCI) awarded a $455,111 Project Grant under CFDA 93.393 "Cancer Cause and Prevention Research" to the Sloan-Kettering Institute for Cancer Research in New York. The 2-year grant, awarded on September 5, 2023, will support research to "Leverage the Hidden Genome to Recover the Missing Heritability of Cancer." The project aims to 1) estimate additional heritability that can be explained by the "hidden genome" (regions of unknown...
This $635,033 federal Project Grant award from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) to The Johns Hopkins University supports research to advance understanding of the genetic basis of a recently recognized cancer-prone syndrome caused by long telomere length. The project aims to identify additional novel mechanisms for this "long telomere syndrome", with the goal of identifying high-risk groups who could benefit from early screening and...
This federal Cooperative Agreement award from the National Cancer Institute (NCI), under the Cancer Cause and Prevention Research (CFDA 93.393) program, will provide $720,252 to the Dana-Farber Cancer Institute, Inc. (DFCI) from April 1, 2025 to March 31, 2030. The project aims to characterize the genetic risk of cancer across diverse populations through multi-ancestry epigenome profiling and chromatin QTL discovery. Key objectives include: 1) Identifying chromatin QTLs (cQTLs) that confer...
This Project Grant award from the National Cancer Institute (CFDA 93.395 Cancer Treatment Research) supports the development and evaluation of an ultra-small epigenetic-regulating nanocarrier for enhanced synthetic lethal therapy. The $362,741 award, effective July 9, 2024 through June 30, 2029, will fund research to optimize a nanocarrier formulation that can effectively deliver a PARP inhibitor (BMN673) and a DNA methylation inhibitor (5-azacytidine) to tumors. The goal is to enhance the...
The National Cancer Institute (NCI) awarded a $764,565 Project Grant under the Cancer Cause and Prevention Research program (CFDA 93.393) to the Sloan-Kettering Institute for Cancer Research. The goal of this five-year study is to validate novel circulating metabolite biomarkers for gastric cancer risk and understand their role in disease etiology. The project will analyze pre-diagnostic plasma samples and epidemiological data from over 1,200 gastric cancer cases and 1,600 matched controls...
This Project Grant award from the National Cancer Institute (NCI) under the Cancer Research Manpower (CFDA 93.398) program will fund a 2-year, $142,295 research project conducted by the Harvard T.H. Chan School of Public Health. The project aims to identify gut microbial and metabolomic biomarkers associated with ultra-processed food (UPF) consumption and their relationship to colorectal cancer (CRC) risk. It will also evaluate the feasibility and initial efficacy of a 6-week medically...